# Carcinogenicity Study of Bupropion

> **NCT01077596** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 50430 (actual)

## Conditions studied

- Depressive Disorder
- Cancer

## Interventions

- **DRUG:** Regular bupropion use
- **DRUG:** Regular SSRI (Selective serotonin reuptake inhibitors) use
- **DRUG:** Regular TCA (Tricyclic antidepressants) use
- **DRUG:** Regular use of any other antidepressant

## Key facts

- **NCT ID:** NCT01077596
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 50430 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01077596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01077596, "Carcinogenicity Study of Bupropion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01077596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*